Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Has Consensus Price Target of $155.00 According to Analysts

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $155.00.

ABVX has been the subject of several research analyst reports. The Goldman Sachs Group assumed coverage on Abivax in a report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price target for the company. Morgan Stanley reissued an “overweight” rating and issued a $180.00 target price on shares of Abivax in a research note on Friday, July 24th. Barclays reaffirmed an “overweight” rating and set a $148.00 price target on shares of Abivax in a research note on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Thursday, October 15th. Finally, Guggenheim reissued a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research note on Tuesday, October 20th.

Abivax Stock Performance

ABVX stock opened at $90.20 on Tuesday. The company’s fifty day moving average price is $95.37 and its 200-day moving average price is $112.69. Abivax has a one year low of $69.81 and a one year high of $148.83. The company has a market capitalization of $7.90 billion, a PE ratio of -14.88 and a beta of 1.36.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The business had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. On average, research analysts predict that Abivax will post -4.14 EPS for the current fiscal year.

Institutional Trading of Abivax

A number of hedge funds and other institutional investors have recently bought and sold shares of ABVX. Eversept Partners LP lifted its holdings in Abivax by 42.0% during the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock valued at $104,048,000 after buying an additional 276,589 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Abivax by 31.6% in the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after purchasing an additional 211,068 shares in the last quarter. Aberdeen Group plc lifted its position in shares of Abivax by 45.8% in the 3rd quarter. Aberdeen Group plc now owns 761,016 shares of the company’s stock worth $75,356,000 after purchasing an additional 238,991 shares during the period. Bank of America Corp DE lifted its position in shares of Abivax by 40.9% in the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after purchasing an additional 213,440 shares during the period. Finally, Two Seas Capital LP bought a new position in shares of Abivax during the third quarter valued at approximately $66,996,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About Abivax

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.